WHO ICTRP trial
A phase II study of definitive chemoradiation therapy using docetaxel…
JPRN-UMIN000025109 · Japan Primary Registries Network (JPRN) · Not Recruiting
Key facts
| Trial ID | JPRN-UMIN000025109 |
|---|---|
| Public title | A phase II study of definitive chemoradiation therapy using docetaxel, nedaplatin, and 5-fluorouracil with modified dose radiation (mDNF-R) followed by S-1 maintenance therapy and salvage therapy for patients with clinical stage IB-IIIC (non-T4) esophageal carcinoma |
| Scientific title | A phase II study of definitive chemoradiation therapy using docetaxel, nedaplatin, and 5-fluorouracil with modified dose radiation (mDNF-R) followed by S-1 maintenance therapy and salvage therapy for patients with clinical stage IB-IIIC (non-T4) esophageal carcinoma - A phase II study of mDNF-R… |
| Primary sponsor | Sapporo Medical University School of Medicine, Department of Medical Oncology |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Not selected |
| Countries | Japan |
| Conditions | Esophageal carcinoma |
| Interventions | Definitive chemoradiation therapy using docetaxel, nedaplatin and 5-fluorouracil (DNF) with concurrent radiotherapy (50.4 Gy) followed by 2-course of additional DNF therapy and 1-year S-1 maintenance therapy. 2) Salvage therapy for patients… |
| Registration date | Jan 12, 2016 |
| Target size | 24 |
| Registry page | center6.umin.ac.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: